Nippon Life India Asset Management Ltd. - Nippon India Mutual Fund - Nippon India Nifty Pharma ETF

NSE: PHARMABEES

SMALL CAP•MCap –

₹26.38₹-0.15 (-0.57%)

Live • NSE

Market cap–

Enterprise value–

52W high₹28.58

52W low₹21.69

Price chart(1Y)

1Y Return:+5.60% (+₹1.40)

H: ₹28.58L: ₹24.17

1W-1.57%

1M-4.07%

3M-1.79%

6M+14.60%

1Y+16.16%

Today at a glance

Day range

₹26.37₹26.94

52 week range

₹21.69₹28.58

Volume1.86M0.42x 20D avg

Free float50.00%-57.90% volume

Nippon Life India Asset Management Ltd. - Nippon India Mutual Fund - Nippon India Nifty Pharma ETF closed at INR26.38 (-0.57%) on volume 0.42x its 20-day average, trading 7.7% below its 52-week high.

Technical analysis

RSI (14)37.4Neutral (30–70)

MACDBEARISHBearish (Below signal)

ATR (14)₹0.81High

SMA 20₹27.14BEARISH

SMA 50₹27.26BEARISH

SMA 100₹26.60BEARISH

SMA 200₹24.99BULLISH

CPR bottom₹26.80

Pivot₹26.71

CPR top₹26.62

Shariah audit

Methodology: AAOIFI Shariah Standard No. 21

FAIL1/4 criteria

Non-Compliant (Business Activity)

Criteria	Numerator	Denominator	Value	Threshold	Status
Interest-bearing debt ratio	–	–	—	≤ 33%	PENDING_DATA
Non-halal income ratio	–	–	0.00%	≤ 5%	FAIL
Illiquid assets ratio	–	–	—	≥ 20%	PENDING_DATA
Receivables ratio	–	–	—	≤ 49%	PASS

Valuation & sector context

MetricCompanySector

P/E—25.00

Forward P/E——

P/B—3.50

EV/EBITDA—18.00

PEG—1.50

Earnings yield—4.00

Growth & profitability

RevenuePAT

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y—

Revenue CAGR 5Y—

PAT CAGR 3Y—

PAT CAGR 5Y—

Operating margin0.00%

Net margin0.00%

Financial health & cash flow

Net debt–Moderate

Interest coverage—xEBIT / interest

CFO / PAT—x3Y average

Net debt / EBITDA—Leverage

Operating cash flow–

Capital expenditure–

Free cash flow–

Fundamental scorecard

Overall50/100

Valuation50/100

Profitability50/100

Financial health50/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Established operational history in the sector

Active institutional participation

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in core business.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)65.46%-12.29% latest vs average

Highest delivery82.96%on 21 Sept

Average volume (20D)4.50MTrading-session average

Conviction trendWeakening-12.29% latest reading

Traded volumeDelivery %

Questions investors ask

Is Nippon Life India Asset Management Ltd. - Nippon India Mutual Fund - Nippon India Nifty Pharma ETF Shariah compliant?

Nippon Life India Asset Management Ltd. - Nippon India Mutual Fund - Nippon India Nifty Pharma ETF is currently screened as Non-Compliant (Business Activity) under AAOIFI Shariah Standard No. 21. Business activity in non-permissible sector: /\basset management\b/i Interest-bearing debt or Market Cap data unavailable for ratio screening.

What is Nippon Life India Asset Management Ltd. - Nippon India Mutual Fund - Nippon India Nifty Pharma ETF's current valuation relative to peers?

Nippon Life India Asset Management Ltd. - Nippon India Mutual Fund - Nippon India Nifty Pharma ETF trades at a P/E of N/A compared to the sector median of 25x, and a Price-to-Book of N/A.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of zero debt. Interest coverage is comfortable.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-19. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.